The importance of KRAS status in managing metastatic colorectal cancer
- Stephen LeongAffiliated withDepartment of Medical Oncology, University of Colorado Cancer Center Email author
- , S. Gail Eckhardt
- , Antonio Jimeno
- , Wells Messersmith
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the past decade, the standard of care for advanced colorectal cancer has been in a state of flux with the introduction of new agents in the treatment of stage IV disease; however, the 5-year survival rate for advanced disease remains low. Investigators are trying to identify biomarkers that may be predictive and/or prognostic for these agents and thereby improve patient outcomes. This article discusses recent discoveries that have identified the importance of KRAS mutational status in predicting responses to epidermal growth factor receptor-targeting antibodies (cetuximab and panitumumab) in the management of metastatic colon cancer.
- The importance of KRAS status in managing metastatic colorectal cancer
Current Colorectal Cancer Reports
Volume 5, Issue 3 , pp 129-134
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links